Aventis To Boost Tetanus Vaccine Production To Meet Needs By Year-End
Executive Summary
Aventis-Pasteur has begun scaling up tetanus vaccine component production and expects to meet U.S. tetanus needs by the end of the year.
You may also be interested in...
DTaP Vaccine Production Is Sufficient For Return To 5-Dose Schedule - CDC
The National Immunization Program estimates that there is sufficient DTaP vaccine in the pipeline to return to the routine five-dose schedule.
DTaP Vaccine Production Is Sufficient For Return To 5-Dose Schedule - CDC
The National Immunization Program estimates that there is sufficient DTaP vaccine in the pipeline to return to the routine five-dose schedule.
Wyeth-Ayerst Acel-Imune Discontinued; DTaP Vaccine Had Sales Of $71 Mil.
Wyeth-Ayerst is discontinuing the DTaP vaccine Acel-Imune, the company said.